Anna Martling, Professor of Surgery at the Department of Molecular Medicine and Surgery, is today presenting the large ALASCCA study at a press conference during the ASCO-GI meeting in San Francisco. The study is a randomized drug trial that began in 2016 and has included approximately 3,500 patients from 33 centers in the Nordic region. The study is evaluating the value of adding aspirin to patients who have a specific genetic change and whether this can reduce the risk of recurrence.
Colorectal cancer affects approximately 7,000 people in Sweden annually. Treatment is mainly surgical. Over the past 20-30 years, treatment has improved significantly with refined surgery, the addition of radiation therapy (for rectal cancer) and improved medical treatment with cytostatics and biological drugs. This has led to increased survival in the disease, but almost half of the patients still suffer from difficult-to-treat relapses of the disease.
ALASCCA (Adjuvant Low-Dose ASA in Colorectal Cancer) is the first randomized, placebo-controlled, biomarker-based multicenter study of adjuvant therapy with ASA in patients with colorectal cancer. The study is nationally comprehensive and all patients with localized colorectal cancer in Sweden have been invited to participate in the study.
"The results from the ALASCCA study, which will be presented shortly, have the potential to change the treatment for patients", says Anna Martling .
The results will be made public on January 25, 2025 https://meetings.asco.org/abstracts-presentations/242108
